SM-UP pair showed a higher agreement in diabetic patients. According to subgroup analyses, Hb A1c level, rather than the duration of diabetes, may determine the agreement of these pachymetry devices. But the difference in CT measurements between devices can still influence clinical diagnosis and treatment. Therefore, these methods are not completely interchangeable.
BackgroundThe aim of this study was to assess the intraocular pressure and ocular biometric parameters in migraine patients during acute migraine attacks and compare them with painless period and healthy controls using a new optical biometer AL-Scan.MethodsIn this prospective, case–control study, the axial length, corneal curvature radius, anterior chamber depth, central corneal thickness, and pupil size of 40 migraine patients during acute migraine attacks and painless period and 40 age- and sex-matched healthy subjects were measured using a AL-Scan optical biometer (Nidek Co., Gamagori, Japan). All patients underwent a complete ophthalmic examination before the measurements. IOP and biometer measurements were taken at the same time of day (10:00–12:00) in order to minimize the effects of diurnal variation.ResultsThere was not a statistically significant difference in intraocular pressure between the migraine patients during acute migraine attacks (15.07 mmHg), painless period (14.10 mmHg), and the controls (15,73 ± 0,81). Also, the ocular biometric parameters did not significantly vary during the acute migraine attacks.ConclusionsFurther studies are needed to evaluate the etiopathologic relationship between intraocular pressure and ocular biometric parameters and acute migraine attack.
Purpose: To evaluate the efficacy of topical fresh frozen plasma (FFP) therapy on clinical symptoms, findings, and prognosis after anterior segment surgeries in patients with ligneous conjunctivitis (LC). Methods: Retrospective case note review. Results: Eleven eyes of 7 cases whose remission was not achieved after medical treatment such as topical corticosteroids, cyclosporine A, and heparin were included in the study. The median age of admission was 19 (1–49) years, median duration of FFP treatment was 48 (15–79) months, median follow-up period was 62 (16–114) months, and median age at symptom onset was 12 (4–252) months. Diagnosis was made according to clinical presentations, plasminogen activities, and response to treatment. Topical FFP that was prepared in our clinic was used in all cases. Surgeries (membrane excision, eyelid surgery, deep anterior lamellar keratoplasty, and cataract surgery) were performed after at least 1 month of FFP treatment. Prosthetic contact lens was applied to one eye. During the follow-up period, recurrences requiring membrane excision and side effects from topical FFP were not observed. Conclusions: LC is a rare membranous conjunctivitis that proceeds with remissions and recurrences. When it was shown that the etiology of LC is plasminogen deficiency, FFP became the only treatment option targeting the etiology. In this study, we observed that the topical FFP is an effective treatment method that prevents recurrence and ensures regression of membranes and safer anterior segment surgeries in LC.
Background: To evaluate the effects of tolterodine on anterior segment and choroidal thickness by using the Pentacam system and optical coherence tomography (OCT) (Pentacam). Methods: A total of 122 eyes of 61 patients (34 female; 27 male) were included in the study. All patients underwent a regular ocular examination and intraocular pressure measurements before and after 3 months of antimuscarinic drug tolterodine treatment, in addition, pupil diameter, anterior chamber depth, anterior chamber volume, anterior chamber angle, and lens thickness were measured through Pentacam (Oculus Inc., Wetzlar, Germany) system. Measurements of choroidal thickness were performed by OCT (Spectralis ® , Heidelberg Engineering, Heidelberg, Germany). Results: The mean age was 58.4 ± 7.3 years and 56.5 ± 11.1 years for female and male patients. The mean intraocular pressure was 15.10 ± 2.75 mmHg before treatment and 15.18 ± 2.65 mmHg after treatment. Pupil diameters were 3.09 ± 0.48 mm before treatment and 3.12 ± 0.43 mm after treatment. Anterior chamber depth, before and after treatment were 2.68 ± 0.65 mm and 2.70 ± 0.61 mm. The mean value for subfoveal choroidal thickness was 267.92 ± 81.35 μm before the administration of tolterodine, whereas the mean choroidal thickness was 271.83 ± 75.42 μm after the administration of tolterodine. The alterations in the subfoveal choroidal thickness were not statistically significant (p = 0.862). Conclusions: After 3 months of therapy with tolterodine, there were no significant changes in anterior segment parameters and choroidal thickness.
Pur po se:To determine the factors that influence surgical success in patients with intermittent exotropia. Ma te ri al and Met hod: We retrospectively evaluated the records of patients with intermittent exotropia who were diagnosed, operated, and followed up. Successful outcome was defined as alignment ≤10 prism diopters (PD) esophoria or exophoria at the last follow-up visit. The clinical findings, exodeviation types, surgical ages, operation types, preoperative and postoperative deviation amounts, presence of anisometropia and amblyopia, presence of A-or V-pattern, and presence of binocular vision and stereoacuity of patients were evaluated. We investigated the independent variables that affected the surgical success in intermittent exotropia patients. Re sults: Among the 379 patients included in the study, 266 (70.18%) underwent surgery, and the success rate was 68.05% (181 patients). In this successful surgery group, mean deviation was 25.82±11.27 PD at near and 30.80±10.59 PD at distance versus 30.93±12.47 PD and 34.92±11.02 PD, respectively, in the unsuccessful surgery group. There was a statistically significant difference between the two groups. Preoperative factors, such as presence of binocular vision preoperatively, and postoperative factors, such as followup period and the patients' deviation amount in the 1st week and 6 th month, were found to affect the surgical outcome. Dis cus si on: The success rate of surgical treatment of intermittent exotropia increases in the patients with presence of fusion and low preoperative deviation amounts. Also, in the early postoperative period, orthophoric or ≤10 PD esophoric patients have a higher final surgical success rate. (Turk J Ophthalmol 2013; 43: 107-12) Özet Amaç: İntermitan ekzotropya tedavisinde cerrahi başarıyı etkileyen faktörleri incelemek. Ge reç ve Yön tem: Kliniğimizde tanı konulup, ameliyat edilen ve takibi yapılan intermitan ekzotropya tanılı hastaların kayıtları retrospektif olarak incelendi. Hastaların klinik bulguları, kayma tipleri, cerrahi geçirdikleri yaşları, uygulanan cerrahi yöntemler, operasyon öncesi ve sonrası kayma miktarları, anizometropi ve ambliyopi varlığı, A-V patern birlikteliği, binoküler görme düzeyleri değerlendirildi. Operasyon sonrası son kontrollerinde hastalarda kayma miktarı 10 prizm dioptri (PD) ve altında ezoforya veya ekzoforya olması başarılı sonuç olarak kabul edildi. İntermitan ekzotropyalı hastalarda cerrahi başarıyı etkileyen bağımsız değişkenler araştırıldı. Sonuçlar: Çalışmaya dahil edilen 379 hastanın 266'sına (%70,18) cerrahi uygulandığı görüldü ve cerrahi başarı oranı %68,05 (181 hasta) idi. Cerrahi başarı grubunda operasyon öncesi ortalama kayma miktarı, yakında 25,82±11,27 PD, uzakta 30,80±10,59 PD iken başarısız cerrahi grubunda sırasıyla 30,93±12,47 PD ve 34,92±11,02 PD idi. İki grup arasında istatistiksel olarak anlamlı farklılık vardı. Preoperatif bir faktör olan binoküler görme varlığının ve postoperatif faktörler olan ortalama takip süresi ile cerrahiden sonraki 1. hafta ve 6. aydaki hastanın kay...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.